Deals Shaping The Medical Industry, October 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
You may also be interested in...
US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Takeda Gets New India Chief, Mandate To Broaden Access
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Need a specific report? 1000+ reports available
Buy Reports